市场调查报告书
商品编码
1368649
母乳寡糖 (HMO) 市场规模 - 按浓度(中性 HMO、酸性 HMO)、按应用(婴儿配方奶粉、膳食补充剂、食品和饮料)及全球预测,2023 - 2032 年Human Milk Oligosaccharides (HMO) Market Size - By Concentration (Neutral HMO, Acidic HMO), By Application (Infant Formula, Dietary Supplements, Food and Beverage) & Global Forecast, 2023 - 2032 |
2023年至2032年,全球母乳寡糖市场将以22.5%的复合年增长率成长。人们对母乳寡糖(HMO)的健康益处(例如其在婴儿免疫系统发育和肠道健康中的作用)的认识不断提高,将推动产业成长。
此外,乳糖不耐症盛行率的上升以及婴儿母乳餵养替代品的转变将促进母乳低聚醣配方奶粉的销售。根据 MedlinePlus 的估计,近 65% 的人类在婴儿期后消化乳糖的能力会下降。此外,正在进行的母乳低聚醣在成人营养和药品等领域的潜在应用研究将为业务成长创造新的机会。
母乳低聚醣製造商和婴儿配方奶粉生产商之间日益加强的伙伴关係和合作将进一步促进市场成长。这种增长将得到对婴儿营养产品中母乳低聚醣纳入监管支持的不断发展的补充。这种合作和监管认可的发展将对推动该行业的成长发挥重要作用。
市场根据集中度、应用和区域进行划分。
根据集中度,到2032 年,酸性HMO 细分市场将呈现可观的复合年增长率。人们对酸性HMO 健康益处的认识不断提高,对专门婴儿营养的需求不断扩大,以及证明其在婴儿健康方面优势的持续研究将促进该细分市场的成长。
到2032 年,膳食补充剂应用领域将在母乳低聚醣市场中占据显着份额。消费者对HMO 潜在健康益处的认识不断提高、其经过验证的益生元特性,以及对功能性和营养补充剂的需求不断扩大等因素,特别是那些针对肠道健康和免疫支持将推动该领域的成长。
从地区来看,在出生率上升、可支配收入增加以及对婴儿营养日益重视等因素的推动下,亚太地区母乳低聚醣(HMO)市场在分析期间将以令人称讚的复合年增长率增长。此外,人们对母乳哺育益处的认识提高以及优质婴儿配方奶粉产品的采用将进一步推动该地区行业的成长。
The global human milk oligosaccharides market will grow at a 22.5% CAGR from 2023 to 2032. The increasing awareness of the health benefits of human milk oligosaccharides (HMOs) such as their role in infant immune system development and gut health, will fuel industry growth.
Additionally, the rising prevalence of lactose intolerance and the shift towards breastfeeding alternatives for infants will boost human milk oligosaccharides-based formula sales. According to estimates from MedlinePlus, close to 65% of the human population experiences a decline in the ability to digest lactose post-infancy. Furthermore, ongoing research into potential applications of human milk oligosaccharides in areas like adult nutrition and pharmaceuticals will create new opportunities for business growth.
The increasing partnerships and collaborations between manufacturers of human milk oligosaccharides and producers of infant formula will further augment market growth. This growth will be complemented by the ongoing evolution of regulatory support for the inclusion of human milk oligosaccharides in infant nutrition products. Such developments in cooperation and regulatory endorsement will play a significant role in driving the industry's growth.
The market is segregated based on concentration, application, and region.
Based on concentration, the acidic HMO segment will reflect a substantial CAGR through 2032. The rising awareness of the health benefits of acidic HMO, expanding demand for specialized infant nutrition, and ongoing research demonstrating their advantages in infant health will foster growth in the segment.
The dietary supplement application segment will hold a noteworthy share of the human milk oligosaccharides market by 2032. Factors such as increasing consumer awareness of the potential health benefits of HMOs, their proven prebiotic properties, and the expanding demand for functional and nutritional supplements, particularly those targeting gut health and immune support will drive growth in the segment.
Regionally, the Asia Pacific human milk oligosaccharides (HMOs) market will grow with a commendable CAGR during the analysis period, driven by factors such as increasing birth rates, rising disposable incomes, and a growing emphasis on infant nutrition. Moreover, heightened awareness of the benefits of breastfeeding and the adoption of premium infant formula products will further drive growth in the regional industry.